oncbrain — oncology meeting digest

AZUR-1

Wed, 04 Nov 2026 00:00:00 GMT

[Early signal] cCR12 68% (investigator) and cCR12+pCR 76% with dostarlimab alone in dMMR/MSI-H LARC, no recurrences to date at 26.3mo median f/u. Eligible: dMMR/MSI-H locally advanced rectal cancer, treatment-naive

SANO

Wed, 04 Nov 2026 00:00:00 GMT

[Confirmatory] 5y OS 50% vs 54%, HR 1.17 (0.77-1.77) active surveillance vs surgery after cCR to nCRT; distant mets 46% vs 29%, P<.01. Eligible: Locally advanced oesophageal cancer, cCR after nCRT

PE-PE

Wed, 04 Nov 2026 00:00:00 GMT

[Early signal] mRFS 25.4 vs 11.0 mo, HR 0.47 (0.24-0.92), p=0.024, adding 1y perioperative pembrolizumab to SABR/surgery MDT in omRCC. Eligible: Oligometastatic RCC, ≤3 mets within 5y of prior nephrectomy, MDT-eligible

DASL-HiCaP

Tue, 03 Nov 2026 00:00:00 GMT

[Early signal] 4-yr MFS-CI 95% vs 88%, HR 0.42 (0.27-0.66), adding darolutamide to 96-wk ADT plus prostate/bed and pelvic nodal RT in very high-risk disease. Eligible: Very high-risk localised PCa, or PSA persistent/recurrent within 1 yr of RP

UNION

Mon, 02 Nov 2026 00:00:00 GMT

[Caveats dominate] 3-yr EFS 91.3% vs 77.4%, HR 0.33 (0.15-0.71), P=0.0029: SCRT → camrelizumab + CAPOX vs long-course CRT → CAPOX in LARC. Eligible: cT3-4 or N+ rectal adenocarcinoma ≤10 cm from anal verge

TOP-1 (BOOG 2016-01)

Mon, 02 Nov 2026 00:00:00 GMT

[Early signal] 5-yr local recurrence 14.8% (95% CI 12.3-17.5) after BCS alone without RT or ET in women ≥70 with low-risk ER+ HER2- BC. Eligible: Women ≥70, low-risk ER+ HER2- T1 BC after BCS, no endocrine therapy

KEYNOTE-975

Sat, 31 Oct 2026 00:00:00 GMT

[Confirmatory] EFS HR 0.97 (95% CI 0.77-1.23), median 15.2 vs 14.7 mo in PD-L1 CPS ≥10: no EFS gain adding concurrent pembro to dCRT in unresectable esophageal/GEJ cancer. Eligible: Untreated unresectable locally advanced ESCC/EAC/GEJ, dCRT candidates

SARON

Sat, 31 Oct 2026 00:00:00 GMT

[Challenges SOC] Consolidation RT added to 1L SACT: mOS 31.0 vs 28.0mo (HR 0.99, p=0.95) despite mPFS 13.9 vs 8.9mo (HR 0.64) in synchronous oligometastatic AGA-negative NSCLC. Eligible: Synchronous oligometastatic AGA-negative NSCLC, 1-5 mets, non-progressing on 1L SACT

EORTC 1420 Best-of

Mon, 26 Oct 2026 00:00:00 GMT

[Caveats dominate] 12-mo MDADI adjusted difference +3.9 points (90%CI -2.7 to +10.5; p=0.326), TOS vs DO-IMRT; no swallowing difference, more mucosal toxicity with DO-IMRT. Eligible: T1-T2 N0-1 OPSCC/SGSCC or T1 N0 HPSCC, fit for TOS or RT

SARON

Sun, 25 Oct 2026 00:00:00 GMT

[Caveats dominate] mOS 31.0 vs 28.0 mo, HR 0.99 (0.63-1.55), adding consolidation RT to SACT in synchronous oligometastatic driver-negative NSCLC; PFS improved, magnitude not given. Eligible: Synchronous 1-5 met driver-negative NSCLC, no PD after induction SACT

DeLLphi-305

Sat, 24 Oct 2026 00:00:00 GMT

[Practice-changing] mOS 21.1 vs 12.7 mo, HR 0.42 (0.32-0.54), adding tarlatamab to durvalumab 1L maintenance in ES-SCLC after chemo-IO induction. Eligible: ES-SCLC, no progression after 1L platinum-etoposide + durvalumab, ECOG 0-1

STAMPEDE, ENZARAD, PROTEUS and DASL in context

Sat, 24 Oct 2026 00:00:00 GMT

ESMO26 round-up of four intensification trials. STAMPEDE Decipher update suggests differential abiraterone benefit in cN0 disease (interaction P=.01).

DASL-HiCaP

Sat, 24 Oct 2026 00:00:00 GMT

[Early signal] 4-yr MFS-CI 95% vs 88%, HR 0.42, adding darolutamide to prostate/bed + pelvic LN RT and 96 wk ADT in very high-risk prostate cancer. Eligible: Very high-risk or N1 prostate, radical or early salvage RT + 2y ADT

PROTEUS Substudy

Sat, 24 Oct 2026 00:00:00 GMT

[Caveats dominate] EFS HR 0.38 (95% CI 0.26-0.55) with perioperative apalutamide + ADT around RP + PLND in HR LPC/LAPC; MFS HR 0.49, nominal p only. Eligible: HR LPC/LAPC, conventionally staged M0, planned RP + PLND